- Among patients with mild cognitive impairment (MCI) who have had reversion to normal cognition, a set of biomarkers may help identify those who will go on to experience subsequent progression to MCI again or to dementia.
Why this matters
- Importance of reliable prognostication for counseling, treatment planning.
- After 3.2 years:
- 71% of patients had stable normal cognition.
- 29% of patients had decline (24% to MCI again, 5% to dementia).
- Compared with stable patients, patients experiencing decline:
- Were older (74 vs 69 years; P=.016).
- Had higher amyloid positron emission tomography standard uptake value ratio (1.21 vs 1.08; P=.026).
- Had higher Luminex cerebrospinal fluid total tau levels (84 vs 53 pg/mL; P=.042).
- Longitudinal cohort study of 61 patients with MCI who had reversion to normal cognition during follow-up of more than 2 years in the Alzheimer’s Disease Neuroimaging Initiative.
- Main outcome: persistent normal cognition vs decline (repeated MCI or dementia).
- Funding: ZonMW Memorabel Grant Program; InnovativeMedicines Initiative Joint Undertaking.
- Small sample.
- Relatively short follow-up.
- Losses to follow-up.